Navigation Links
Respironics, Inc. Completes Voluntary Recall Notification of a Limited Number of Trilogy 100 Ventilators
Date:1/12/2012

MURRYSVILLE, Pa., Jan. 12, 2012 /PRNewswire/ -- Respironics, Inc. announced today that it has completed notifying customers of a voluntary recall of 52 Trilogy Model 100 ventilators in the United States and has confirmed that 51 have already been removed from use. The recall was initiated on October 11, 2011 to address a manufacturing issue that may have affected these ventilators. Respironics received no reports of ventilator malfunctions, failures or injuries related to this issue.  

The Trilogy 100 ventilator provides portable volume and pressure support ventilation for adult and pediatric use in both invasive and noninvasive applications. Other Trilogy ventilator models distributed in the United States, the Trilogy 200 and 202, were not affected by this recall.

An internal Respironics data review found that when the blower assemblies of the recalled ventilators were manufactured, the force used to press the impeller onto the blower motor shaft was less than the specified minimum force. This could result in the impeller moving up the motor shaft and coming in contact with the inside of the blower housing. If this were to occur, it could cause noise, the sounding of an inoperative ventilator alarm, or a blower failure. In the event of a blower failure, the ventilator would stop delivering therapy and a high priority alarm would sound to alert the caregiver to immediately respond. Failure to respond could result in the potential for harm or death of a ventilator dependent patient.

Respironics began notifying its United States distributors, providers, sales personnel and customers of the recall by telephone on October 11, 2011.  Although the Respironics customers who received the affected units have already confirmed receipt of our notice, customers who have questions about the recall may contact Respironics Customer Service at 1-877-387-3311. Please see attached serial number list of affected units that were recalled.

Respironics notified the U.S. Food & Drug Administration (FDA) of its decision to voluntarily recall the affected product on October 7, 2011. Any adverse reactions experienced with the use of this product should be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch. Adverse reactions and/or quality problems should also be reported to Respironics at 1-877-387-3311. 

Serial Numbers of Domestic Devices RecalledTV111021835

TV111031420

TV111032905

TV111032935TV111022832

TV111031462

TV111032906

TV111032938TV111030853

TV111031554

TV111032909

TV111032939TV111030932

TV111032809

TV111032912

TV111032940TV111030947

TV111032811

TV111032913

TV111033001TV111030976

TV111032812

TV111032914

TV111033004TV111030978

TV111032822

TV111032920

TV111033005TV111031001

TV111032827

TV111032923

TV111033006TV111031011

TV111032829

TV111032924

TV111033009TV111031037

TV111032830

TV111032925

TV111033010TV111031045

TV111032832

TV111032926

TV111033016TV111031403

TV111032833

TV111032929

TV111033018TV111031413

TV111032901

TV111032934

TV111033019 


'/>"/>
SOURCE Respironics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics Completes Acquisition of S.E.D. Medical Laboratories
2. Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy
3. Weikang Bio-technology Group, Inc. Completes HQ Relocation After Purchasing Building for $14 Million and Answers Questions About its Third Quarter Financials
4. Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
5. Valeant Pharmaceuticals Completes Acquisition of iNova
6. Valeant Pharmaceuticals Completes Acquisition of Dermik
7. Vermillion Completes the Acquisition of Correlogic Systems Ovarian Cancer Diagnostics Business
8. Perceptive Informatics Completes Over 500 System Integrations as the Biopharma Industry Continues to Adopt Seamless eClinical Solutions
9. Sotera Wireless Completes $12.2 Million Series D Financing, Signs Agreement with Cerner
10. Concord Medical Completes its Twelfth Annual Academic Conference
11. China Health Resource Completes Key Research Project - New Proprietary Product Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
Breaking Medicine Technology:
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):